Sugi Predict

Sugi Predict / Compounds / SCHEMBL283052

SCHEMBL283052

SCHEMBL283052

CC(C)(CO)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ TSHR P16473 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ IDO1 P14902 1/20 0.41
▸ AGXT P21549 1/20 0.40
▸ SLC6A2 P23975 3/20 0.39
▸ SLC6A3 Q01959 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ LIPE Q05469 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ CCR5 P51681 1/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19775161 0.89 KDM4E (0.40) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL18932848 0.85 KDM4E (0.42) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL21838058 0.84 TSHR (0.41) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL11633545 0.83 KDM4E (0.47) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL21327698 0.83 TSHR (0.48) TSHRALDH1A1IDO1AGXTSLC6A2
SCHEMBL15012421 0.82 KDM4E (0.46) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL11249114 0.82 KDM4E (0.46) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL12879586 0.81 TSHR (0.46) KDM4ETSHRALDH1A1IDO1AGXT
SCHEMBL19777982 0.80 TSHR (0.41) KDM4EPOLBTSHRALDH1A1IDO1
SCHEMBL9903817 0.79 TSHR (0.44) TSHRALDH1A1IDO1AGXTSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
EP-4107164-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP disclosed
EP-4644394-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2025-11-05 — — EP disclosed
EP-4106876-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-17 — — EP disclosed
EP-4573088-A1 HETEROCYCLE RBM39 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-06-25 — — EP disclosed
CN-114901280-B MrgprX2 antagonists and uses thereof 德米拉公司 2025-05-27 — — CN disclosed
US-12264173-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2025-04-01 — — US disclosed
CN-119630658-A Heterocyclic RBM39 modulators 递归医药公司 2025-03-14 — — CN disclosed
CN-115175735-B Antiviral compounds 吉利德科学公司 2025-03-04 — — CN disclosed
US-20250002513-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-01-02 — — US disclosed
EP-2133349-A1 Kinase inhibitors Takeda San Diego, Inc. (US) 2009-12-16 — — EP disclosed
WO-2009129401-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 — — WO disclosed
EP-2081930-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2009-07-29 — — EP disclosed
US-20090156557-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-06-18 — — US disclosed
US-20090082464-A1 EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. 2009-03-26 — — US disclosed
WO-2009033079-A1 EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2009-03-12 — — WO disclosed
EP-1931669-A1 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-06-18 — — EP disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 KDM4E 3217/4885POLB 2791/4885TSHR 546/4885
US-12264173-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 KDM4E 3679/4885POLB 4269/4885TSHR 2321/4885
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 KDM4E 1545/4885POLB 904/4885TSHR 3650/4885
US-20090156557-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 KDM4E 1216/4885POLB 1053/4885TSHR 3837/4885
US-20250002513-A1 ANTIVIRAL COMPOUNDS EIF2AK2, MAVS, DUT KDM4E 547/4885POLB 1193/4885TSHR 4684/4885
US-20090082464-A1 EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE AASDHPPT, ADSL, NAPEPLD KDM4E 1314/4885POLB 2937/4885TSHR 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.